CLINICAL_TRIALS ClinicalTrials.gov record update

A Global, Phase 3, Open-Label, Single Arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg (Triptorelin Mesylate Injection, 22.5 mg) in Patients With Advanced Prostate Cancer (KATANA E6M)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06795191
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:52.847801+00:00
Published At: 2025-04-27T00:00:00+00:00
Record Updated At: 2025-04-27
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Prostate Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-04-27"
protocolSection.identificationModule.nctId: "NCT06795191"
protocolSection.identificationModule.officialTitle: "A Global, Phase 3, Open-Label, Single Arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg (Triptorelin Mesylate Injection, 22.5 mg) in Patients With Advanced Prostate Cancer (KATANA E6M)"
protocolSection.statusModule.overallStatus: "WITHDRAWN"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.